Page 630«..1020..629630631632..640650..»

Charles River offloads Japanese research model site, Swedish gene therapy CDMO for $115M – FierceBiotech

Posted: October 16, 2021 at 2:32 am

Charles River Laboratories is parting ways with two divisionsfor about $115 million, including a Swedish contract developer and manufacturer site snagged in the $875 million acquisition of Cognate Bioservices in March.

The Japanese research models and services unit was sold to Jackson Laboratory for about $63 million in cash, while the gene therapy CDMO site in Sweden was handed over to a private investor group for about $52 million in cash as of Tuesday, according to a statement. The CDMO deal could grow by another $25 million upon potential contingent payments, Charles RiversaidTuesday.

The research and services operations has 260 employees and bolstered Charles River's 2020 revenue by $46 million. Charles River and Jackson Laboratory have been distribution partners on the unit for more than two decades. Following the divestiture, the companies have a technology license agreement for Jackson to produce and distribute the research models in Japan.

RELATED:Charles River jumps into cell and gene therapy manufacturing with $875M Cognate buy

The gene therapy manufacturing plant in Sweden was picked up through Charles River's acquisition of Cognate in the spring. That plant, which has 130 employees,produces plasmid DNA and helped add $10 million to the books last year.

While the plant is no longer a part of Charles River, the CRO still has access to cell and gene therapy CDMO capabilities at operations in the U.S. and the U.K., the company said.

Charles River expects revenue to drop nearly $20 million as a result of the sales.

Follow this link:
Charles River offloads Japanese research model site, Swedish gene therapy CDMO for $115M - FierceBiotech

Posted in Gene therapy | Comments Off on Charles River offloads Japanese research model site, Swedish gene therapy CDMO for $115M – FierceBiotech

5 Slides: Gene therapy and the promise for rare disease – State of Reform – State of Reform

Posted: October 16, 2021 at 2:32 am

Gene therapy represents a new generation of medicine that shows great promise in the fight against rare genetic diseases. The potential long-term transformative benefits could reduce, or even eliminate the ongoing costs of supporting patients and managing diseases. In this conversation, thought leaders will discuss the promise of gene therapy, how policy makers are responding, and what obstacles stand in the way of wide-spread gene therapy treatments.

Date: Thursday, Oct. 21st, 2021

Time: 12:00 1:00pm PDT

Panelists:

Jennifer Hodgeis the US Rare Neurology Medical Team Lead at Pfizer. Over the past 9 years, she has contributed in roles of increasing responsibility across Early Pipeline/Gene Therapy, Sickle Cell Disease, Hemophilia and I&I where she played an important role in the US & EU launches of XELJANZ for Rheumatoid arthritis. She received her PhD in Immunology and completed two Post-Doctoral Fellowships at Harvard Medical School & the Yale University School of Medicine.

Carolina Sommer is the Founder of the Northwest Rare Disease Coalition, Founder of the Seattle Rare Disease Fair, Co-Founder of the ABC Kind Program, and Author of the Lucys Journey books. She is also a member of the Rare Disease Access Working Group with EveryLife Foundation, We Work for Health, Voters for Cures, and the WA Health Access Network.

Ryan Fischer serves as the Chief Advocacy Officer for Parent Project Muscular Dystrophy and has been with the organization for 16 years. Within PPMD, Ryan oversees patient advocacy, patient-focused drug development initiatives including patient-preference research, and the strategic development of the largest patient reported registry in Duchenne developed by PPMD, The Duchenne Registry.

Read more here:
5 Slides: Gene therapy and the promise for rare disease - State of Reform - State of Reform

Posted in Gene therapy | Comments Off on 5 Slides: Gene therapy and the promise for rare disease – State of Reform – State of Reform

Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial – DocWire News

Posted: October 16, 2021 at 2:32 am

This article was originally published here

Neurology. 2021 Oct 14:10.1212/WNL.0000000000012952. doi: 10.1212/WNL.0000000000012952. Online ahead of print.

ABSTRACT

OBJECTIVE: To report final, 36-month safety and clinical outcomes from the PD-1101 trial of NBIb-1817 (VY-AADC01) in participants with moderately advanced Parkinsons disease (PD) and motor fluctuations.

METHODS: PD-1101 was a phase 1b, open-label, dose escalation trial of VY-AADC01, an experimental AAV2 gene therapy encoding the human aromatic L-amino acid decarboxylase (AADC) enzyme. VY-AADC01 was delivered via bilateral, intraoperative MRI-guided putaminal infusions to 3 cohorts (n = 5 participants per cohort): cohort 1, 7.51011 vector genomes (vg); cohort 2, 1.51012 vg; cohort 3, 4.71012 vg.

RESULTS: No serious adverse events (SAEs) attributed to VY-AADC01 were reported. All 4 non-vector-related SAEs (atrial fibrillation and pulmonary embolism in 1 participant and 2 events of small bowel obstruction in another participant) resolved. Requirements for PD medications were reduced by 21-30% in the 2 highest dose cohorts at 36 months. Standard measures of motor function (PD diary, UPDRS III off-medication and on-medication scores), global impressions of improvement (CGI-I, PGI-I), and quality of life (PDQ-39) were stable or improved compared with baseline at 12, 24, and 36 months following VY-AADC01 administration across cohorts.

CONCLUSIONS: VY-AADC01 and the surgical administration procedure were well-tolerated and resulted in stable or improved motor function and quality of life across cohorts, as well as reduced PD medication requirements in cohorts 2 and 3 over 3 years.Clinicaltrials.gov identifier: NCT01973543 CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that, in patients with moderately advanced PD and motor fluctuations, putaminal infusion of VY-AADC01 is well tolerated and may improve motor function.

PMID:34649873 | DOI:10.1212/WNL.0000000000012952

See the original post:
Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial - DocWire News

Posted in Gene therapy | Comments Off on Safety of AADC Gene Therapy for Moderately Advanced Parkinson Disease: Three-Year Outcomes From the PD-1101 Trial – DocWire News

Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress – Yahoo Finance

Posted: October 16, 2021 at 2:32 am

Nine accepted abstracts demonstrate broad potential of the companys HSC gene therapy approach to treat severe neurodegenerative diseases and immunological disorders

BOSTON and LONDON, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the acceptance of nine abstracts at the upcoming European Society of Gene & Cell Therapy Congress (ESGCT) taking place virtually from October 19-22.

Clinical and pre-clinical data from across the companys hematopoietic stem cell (HSC) gene therapy portfolio will be featured in two oral and seven poster presentations, including an update on the ongoing proof-of-concept study of OTL-201 for the treatment of Mucopolysaccharidosis type IIIA (MPS-IIIA, also known as Sanfilippo syndrome type A), pre-clinical data from OTL-204 in frontotemporal dementia (FTD), as well as proof-of-principle for longitudinal monitoring of vector integration sites using Liquid Biopsy Integration Site sequencing (LiBIS-seq).

Additionally, Orchards scientific advisory board member and clinical collaborator Alessandra Biffi, M.D., professor of pediatrics, University of Padua and chief of the Pediatric Onco-hematology Unit of Padua Hospital, will be giving an invited presentation on the HSC gene therapy landscape for the treatment of neurodegenerative disorders, which will include an overview of several of the companys investigational programs.

The presentations are listed below, and the full program is available online on the ESGCT website. All times are Central European Summer Time (CEST).

Oral Presentation Details:

Haematopoietic reconstitution dynamics of mobilized peripheral blood- and bone marrow-derived haematopoietic stem/progenitor cells after gene therapyPresenting Author: Andrea Calabria, Ph.D., San Raffaele Telethon Institute for Gene TherapyAbstract Number: OR049Date/Time: Friday, October 22, 2021 at 10:01 CEST

Longitudinal monitoring of vector integration sites in in vivo GT approaches by Liquid-Biopsy-Integration-Site-SequencingPresenting Author: Daniela Cesana, Ph.D., San Raffaele Telethon Institute for Gene TherapyAbstract Number: OR058Date/Time: Friday, October 22, 2021 at 12:46 CEST

Story continues

Poster Presentation Details:

All posters will be available on demand starting October 19, 2021 on the ESGCT website.

Development of an ex vivo Gene Therapy for Frontotemporal Dementia (FTD)Presenting Author: Yuri Ciervo, Ph.D., division of pediatric Hematology,Oncology and Stem Cell Transplantation, Womans and Child Health Department, University of Padova, Padova, ItalyAbstract Number: P077

Optimized Lentiviral Transduction Process for ex vivo CD34+ Hematopoietic Stem Cell Gene Therapy Drug Product ManufacturePresenting Author: Saranya Elavazhagan, Orchard TherapeuticsAbstract Number: P271

Clinical Trial Update: Ex-vivo autologous stem cell gene therapy in MPSIIIAPresenting Author: Brian Bigger, Ph.D., University of ManchesterAbstract Number: P361

Dissecting bone remodelling mechanisms and hematopoietic stem cell gene therapy impact in Mucopolysaccharidosis type I Hurler bone defectsPresenting Author: Ludovica Santi, Ph.D., San Raffaele Telethon Institute for Gene TherapyAbstract Number: P157

Hematopoietic reconstitution and lineage commitment in HSC GT patients are influenced by the disease backgroundPresenting Author: Andrea Calabria, Ph.D., San Raffaele Telethon Institute for Gene TherapyAbstract Number: P181

Kinetics and composition of haematopoietic stem/progenitors mobilized cells upon G-CSF and Plerixafor administration in transplant donor or patients undergoing autologous gene therapyPresenting Author: Luca Basso-Ricci, San Raffaele Telethon Institute for Gene TherapyAbstract Number: P174

Role of peripheral blood circulating haematopoietic stem/progenitor cells during physiological haematopoietic maturation and after gene therapyPresenting Author: Pamela Quaranta, San Raffaele Telethon Institute for Gene TherapyAbstract Number: P186

About Orchard TherapeuticsAt Orchard Therapeutics, our vision is to end the devastation caused by genetic and other severe diseases. We aim to do this by discovering, developing and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patients own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease in a single treatment.

In 2018, the company acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Today, Orchard has a deep pipeline spanning pre-clinical, clinical and commercial stage HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit http://www.orchard-tx.com, and follow us on Twitter and LinkedIn.

Availability of Other Information About OrchardInvestors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchards investor relations website and may include additional social media channels. The contents of Orchards website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Contacts

InvestorsRenee LeckDirector, Investor Relations+1 862-242-0764Renee.Leck@orchard-tx.com

MediaBenjamin NavonDirector, Corporate Communications+1 857-248-9454Benjamin.Navon@orchard-tx.com

Read more here:
Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress - Yahoo Finance

Posted in Gene therapy | Comments Off on Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress – Yahoo Finance

Dr Aisha Pandor: How this award winning Human Genetics scientist developed an app to help keep your house clean – IOL

Posted: October 16, 2021 at 2:31 am

Durban - Dr Aisha Pandor needed help around her house one December many years ago but could not find a trustworthy domestic worker quick enough.

Her frustration led the award-winning scientist with a PhD in Human Genetics and business management graduate, to co-found SweepSouth, the countrys first, on-demand cleaning app whichconnects busy people to trusted, background-checked cleaning professionals.

Pandors foray into the on-demand world of a business app came from her inherent curious personality and an enquiring mind that came from growing up in a family of successful and professional people.

Pandor, 36, was a guest speaker on a recent virtual webinar hosted by MANCOSA, a private higher education institution, where she provided students and graduates with practical tools and tips to successfully improve their employability and progress in their chosen career.

Explaining how she came up with the idea for SweepSouth, Pandor said one day during the December holidays some years ago, she was trying to look for a stand-in domestic worker to help out around the house, when she came up with the genius idea.

Pandor drew inspiration from online shopping and food delivery apps and together with her husband, they created the award-winning app.

She wanted to have greater interaction with people,and find out how best to organise domestic work and address the mutual needs of employers.

While studying for my PhD, I always thought about what type of work I would do and whether that work would be aligned with my purpose in life, she said.

The SweepSouth app was launched seven years ago, focusing on changing the mindset of home service professionals.The value of having supportive networks such as a partner, colleagues and family play an important role when having your own business, Pandor said.

She message to students and graduates was: you cannot be taught how to become an entrepreneur, but the skills learnt in courses will provide you with the confidence to become one.

The best learning comes from being able to do things on your own. Having self-confidence and learning to sell yourself by selling your product will be essential for entrepreneurship.

I learnt to become a source of strength and lead people through unforeseen circumstances such as the pandemic.

Entrepreneurship is challenging and there should be no shame in failing as long as you have tried your best and you are aware of the mistakes made and have learnt from them, she said.

Pandor said that success for her is living in the present and trying to make the best out of any day, whilst aligning her purpose in life and being of public service.

She said SweepSouth continues to be a platform that helps combat unemployment and underemployment by helping people find dignified jobs, and contribute to being the voice of women with no voice in public.

IOL

See the original post:
Dr Aisha Pandor: How this award winning Human Genetics scientist developed an app to help keep your house clean - IOL

Posted in Human Genetics | Comments Off on Dr Aisha Pandor: How this award winning Human Genetics scientist developed an app to help keep your house clean – IOL

Popular theory of Native American origins debunked by genetics and skeletal biology – EurekAlert

Posted: October 16, 2021 at 2:31 am

A widely accepted theory of Native American origins coming from Japan has been attacked in a new scientific study, which shows that the genetics and skeletal biology simply does not match-up.

The findings, published today in the peer-reviewed journal PaleoAmerica, are likely to have a major impact on how we understand Indigenous Americans arrival to the Western Hemisphere.

Based on similarities in stone artifacts, many archaeologists currently believe that Indigenous Americans, or First Peoples, migrated to the Americas from Japan about 15,000 years ago.

It is thought they moved along the northern rim of the Pacific Ocean, which included the Bering Land Bridge, until they reached the northwest coast of North America.

From there the First Peoples fanned out across the interior parts of the continent and farther south, reaching the southern tip of South America within less than two thousand years.

The theory is based, in part, on similarities in stone tools made by the Jomon people (an early inhabitant of Japan, 15,000 years ago), and those found in some of the earliest known archaeological sites inhabited by ancient First Peoples.

But this new study, out today in PaleoAmerica the flagship journal of the Center for the Study of the First Americans at Texas A&M University suggests otherwise.

Carried out by one of the worlds foremost experts in the study of human teeth and a team of Ice-Age human genetics experts, the paper analysed the biology and genetic coding of teeth samples from multiple continents and looked directly at the Jomon people.

We found that the human biology simply doesnt match up with the archaeological theory, states lead author Professor Richard Scott, a recognized expert in the study of human teeth, who led a team of multidisciplinary researchers.

We do not dispute the idea that ancient Native Americans arrived via the Northwest Pacific coastonly the theory that they originated with the Jomon people in Japan.

These people (the Jomon) who lived in Japan 15,000 years ago are an unlikely source for Indigenous Americans. Neither the skeletal biology or the genetics indicate a connection between Japan and the America. The most likely source of the Native American population appears to be Siberia.

In a career spanning almost half a century, Scott a professor of anthropology at the University of Nevada-Reno has traveled across the globe, collecting an enormous body of information on human teeth worldwide, both ancient and modern. He is the author of numerous scientific papers and several books on the subject.

This latest paper applied multivariate statistical techniques to a large sample of teeth from the Americas, Asia, and the Pacific, showing that quantitative comparison of the teeth reveals little relationship between the Jomon people and Native Americans. In fact, only 7% of the teeth samples were linked to the non-Arctic Native Americans (recognized as the First Peoples).

And, the genetics show the same pattern as the teethlittle relationship between the Jomon people and Native Americans.

This is particularly clear in the distribution of maternal and paternal lineages, which do not overlap between the early Jomon and American populations, states co-author Professor Dennis ORourke, who was joined by fellow human geneticists and expert of the genetics of Indigenous Americans at the University of Kansas, Jennifer Raff.

Plus, recent studies of ancient DNA from Asia reveal that the two peoples split from a common ancestor at a much earlier time, adds Professor ORourke.

Together with their colleague and co-author Justin Tackney, ORourke and Raff reported the first analysis of ancient DNA from Ice-Age human remains in Alaska in 2016.

Other co-authors include specialists in Ice-Age archaeology and ecology.

Shortly before publication of the paper, two other new studies on related topics were released.

A new genetics paper on the modern Japanese population concluded that it represents three separate migrations into Japan, rather than two, as previously believed. It offered more support to the authors conclusions, however, about the lack of a biological relationship between the Jomon people and Indigenous Americans.

And, in late September, archaeologists reported in another paper the startling discovery of ancient footprints in New Mexico dating to 23,000 years ago, described as definitive evidence of people in North America before the Last Glacial Maximumbefore expanding glaciers probably cut off access from the Bering Land Bridge to the Western Hemisphere. It remains unclear who made the footprints and how they are related to living Native Americans, but the new paper provides no evidence that the latter are derived from Japan.

Professor Scott concludes that the Incipient Jomon population represents one of the least likely sources for Native American peoples of any of the non-African populations.

Limitations of the study include that available samples of both teeth and ancient DNA for the Jomon population are less than 10,000 years old, i.e., do not antedate the early Holocene (when the First Peoples are understood to arrive in America).

We assume, the authors explain however, that they are valid proxies for the Incipient Jomon population or the people who made stemmed points in Japan 16,00015,000 years ago.

Human tissue samples

Peopling the Americas: Not Out of Japan

13-Oct-2021

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read more:
Popular theory of Native American origins debunked by genetics and skeletal biology - EurekAlert

Posted in Human Genetics | Comments Off on Popular theory of Native American origins debunked by genetics and skeletal biology – EurekAlert

New stem cell identified by Sanford Burnham Prebys researchers offers hope to people with rare liver disease – Newswise

Posted: October 16, 2021 at 2:31 am

Newswise LA JOLLA, CALIF. October 11 Researchers from Sanford Burnham Prebys have discovered a new source of stem cells just outside the liver that could help treat people living with Alagille syndrome, a rare, incurable genetic disorder in which the bile ducts of the liver are absent, leading to severe liver damage and death. The findings, published recently in the journal Hepatology,have extensive biomedical implications for Alagille syndrome and for liver disease in general, including cancer.

Weve been aware of the regenerative power of the liver for a long time, possibly even going back to the ancient Greek myth of Prometheus, says lead authorDuc Dong, Ph.D., an associate professor in theHuman Genetics Programat Sanford Burnham Prebys. But the existence and nature of liver stem cells remains an intensely debated topic.

The new study suggests that the reason these cells have been so hard to find may be that researchers have been looking in the wrong place.

The stem cells that we found are actually outside the liver, not within it, which may have made their discovery difficult, adds Dong. We think these outside the box liver stem cells act more like reserves, only traveling into the liver when all other options are exhausted. It only requires a few of these cells to enter the liver and multiply to repopulate all of the cells lost to the disease.

Over 4 thousand babies each year are born with Alagille syndrome, which is caused by a mutation that prevents duct cells from forming in the liver. And while the syndrome can occasionally resolve naturally, and there are treatments available to manage the symptoms, the disease is incurable, carrying a 75% mortality rate by late adolescence for those without a liver transplant.

"We have known and supported Dr. Dong for years and we feel the work he and his team have done on this disease to date is extraordinary," says Cher Bork, Executive Director of the Alagille Syndrome Alliance. "Hope can be difficult to come by for families dealing with any incurable disease, and discoveries like this help give that hope back to families living with this life-dominating condition."

Using zebrafish, which have many of the same genes and cellular pathways as humans, Dongs research team were able to create a model of Alagille syndrome by selectively deactivating genes associated with Alagille syndrome. These genes encode for chemical messengers from the Notch pathway, a signaling system found in most animals that is involved in embryonic development and adult cell maintenance.

Our work suggests that there is potential for liver regeneration in Alagille patients, but because this signaling pathway is mutated, the regenerative cells fail to fully mature into functioning liver duct cells, says Dong.

In further animal studies, the team showed that by genetically restoring this signaling pathway, the regenerative cells could remobilize to form liver ducts, restoring the function of the liver and improving survival. The researchers are now leveraging their discovery to develop new therapies for Alagille syndrome.

Weve shown not just that regeneration is possible in models of Alagille syndrome, but, importantly, how it can be enhanced, says Dong. These missing duct cells can regenerate if Jagged/Notch is restored, and our lab has developed the first drug that can boost this pathway.

While the new drug requires further studies to advance into clinical trials, the team has already found that it could enhance regeneration and survival in animal models and can trigger the Notch pathway in cells from Alagille patients. These results will be published in separate studies.

Were hopeful that this drug will restore the regenerative potential of the liver in Alagille patients, to be more like the liver of Prometheus, adds Dong.

###

About Sanford Burnham Prebys Medical Research Institute

Sanford Burnham Prebys is a preeminent, independent biomedical research institute dedicated to understanding human biology and disease and advancing scientific discoveries to profoundly impact human health. For more than 40 years, our research has produced breakthroughs in cancer, neuroscience, immunology and childrens diseases, and is anchored by our NCI-designated Cancer Center and advanced drug discovery capabilities. For more information, visit us atSBPdiscovery.orgor on Facebookfacebook.com/SBPdiscoveryand on Twitter@SBPdiscovery.

See the rest here:
New stem cell identified by Sanford Burnham Prebys researchers offers hope to people with rare liver disease - Newswise

Posted in Human Genetics | Comments Off on New stem cell identified by Sanford Burnham Prebys researchers offers hope to people with rare liver disease – Newswise

10 Surprising Facts About Birth Control (That You Probably Never Knew) – YourTango

Posted: October 16, 2021 at 2:31 am

The topic of birth control has taken progressive strides over the last few years, and its transparency helped make reproductive education and products more accessible. Yet the fight for reproductive freedom is far from over in the U.S alone, states like Texas and Florida recently passed appalling laws banningabortions.

However, women like Elizabeth Ruzzo, who received her PhD from Duke University in human genetics and genomics, are leading the charge toward change.

Ruzzo is the founder and CEO of adyn, which is a medical company that strives to make the birth control experience easier by ensuring inclusiveness and patient-centricity.

"Because most clinical research is based on single-sex studies of males, women, on the whole, are disproportionately affected. Implicit bias in healthcare is real and well-documented," says Ruzzo."Medical gaslighting is an unfortunate reality which disproportionately impacts BIPOC, LGBTQ, and women, and has real & measurable consequences that can result in life-threatening scenariosthe most blatant being maternal mortality rates in non-Hispanic black women and American Indian/Alaska Native women."

RELATED: Are Women Really More At Risk Taking Birth Control Than The Johnson & Johnson Vaccine?

While female ob-gyns are now the majority, the gynecology field was historically dominated by men. Even as recently as 1970, only 7% of women were gynecologists. And while women have contributed to its creation, IUDs have historically been designed by men.

"The unfortunate fact is that our scientific knowledge of women and people of non-European descent is insufficient," says Ruzzo. "Women werent required to be included in clinical trials in the US until 1993, which led to less research around womens health as well as less knowledge about how women experience diseases and conditions that impact everybody."

Ruzzo believes it's important for inventors and decision-makers to not only consider, "a womans reproductive and health goals, but also her preferences when considering a birth control method." And according to her, both copper and hormonal IUDs are a highly effective method of birth control that can workwell for some people.

The way women have been advised to take contraceptive pills in the last 60 years is directly linked to Catholicism(namely, the Pope). Oral contraceptive pills are designed to be taken for 21 days, followed by a seven-day break. During this break, women refrain from taking the pill, which leads to vaginal bleeding. It should be notedthis method, however, increases the likelihood of unplanned pregnancies.

Carl Djerassi, a Bulgarian-American chemist, was nicknamed the "father of the pill" for his contribution to the development of oral contraceptive pills. Djerassi said the seven-day break was an intentional design with one very specific purpose in mind to persuade the Vatican to accept contraception. The hope was that the Church would view the pill as an "extension" of the natural menstrual cycle.

Planned Parenthood found that access to the pill before the age of 21 was the most influential factor in enabling women who were in college to stay in college. After the legalization of birth control,the number of women who complete higher education is now six times what it was before!

Another fun fact: women also make up the majority of undergraduate students in the U.S.

Many will be surprised to learn that the synthetic estrogen found in the birth control pill has unexpected effects on aquatic ecosystems. A British study found that synthetic estrogen negatively impacted the reproductive cycles of the fathead minnow. It interfered with the species' ability to reproduce and nearly lead to the population's extinction.

And as recently as 2020, another study showed that estrogenic steroids are more potent than previously thoughtand can further harm fish populations by malformations, decreased egg production, and DNA methylation, which represses gene transcription.

A common misconception Ruzzo often hearsis that "Side effects and birth control are a package deal; its just the price to pay for avoiding unwanted pregnancies."

"Side effects do not have to be part of your experience with birth control," Ruzzo explains.

"The best birth control is not only effective, but side-effect free. The best birth control for you is the one that is optimized for your body, your genetics, and your preferences."

This is why Ruzzo emphasizes the importance of choosing a method that works best for your individual body a pill that works for one person may not work for you.

RELATED:Where & How To Get Birth Control During A Pandemic

The man responsible was an American post inspector named Anthony Comstock, whose "anti-obscenity" crusade was fueled by his Christian faith.

Comstock drafted an anti-obscenity bill in 1872, which included a ban on contraceptives, and took it toWashington. The Comstock Act was later passed by Congress on March 3, 1873, and defined contraceptives as "obscene and illicit." In turn, the statute made it a federal offense to distribute birth control through the mail or across state lines.

These laws remained unchallenged until birth-control advocate Margaret Sanger was arrested in 1916 for opening the first birth control clinic in America. Her initial arrest is whatprompted the first successful change in the law.

Ancient Egyptian and Mesopotamian women used crocodile dung, which was mixed with other ingredients, to create a type of pessary.The Egyptians also used honey and acacia fruit & leaves as spermicides, which they would insert inside of themselves before having sex.

In Greece, the philosopher Aristotle proposed that women should use olive and cedar oils to decrease sperm mobility. Greek and Roman women also used an oral contraceptive called "silphium," which was a type of giant fennel that eventually became extinct due to its extreme usage.

Join now for YourTango's trending articles, top expert advice and personal horoscopes delivered straight to your inbox each morning.

Globally, ancient women from civilizations like Egypt, Assyria, Greece, and China all consumed liquid mercury, lead, or arsenic to prevent unwanted pregnancies. While this was technically an effective method, these poisons lead to horrific consequences such as organ failure, brain damage, anddeath.

All of which have varying formulations, Ruzzo says. "Having that much choice is a blessing and a curse: there is no way to know whether you or your doctor are choosing the right one - until now! This is the problem Adyn is solving."

Other methods besidespills and UIDs are birth control shots, implants, and patches, as well as vaginal rings, diaphragms, spermicide, and tubal ligation/vasectomy.

According to Ruzzo, the most effective form of birth control is the one picked based on your unique biology one that is optimized for your body, your genetics, and your preferences. "There are statistics about birth control method efficacy, but pinpointing one as singularly more effective than another is complicated," she adds.

Dr. Sarah Hill, a research psychologist and professor whostudieswomen, health, and sexual psychology,suggestedbirth control pills can, "influence pretty much everything that matters when it comes to love, sex, and relationships."

Though Hill specifies this research is still"in its infancy," there's already data to back this theory up. One study showed that heterosexual women who started taking the pill found men with "less masculine" faces to be more attractive. A second study confirmed that not only do pill-taking women prefer less masculine features; they are also more likely to choose such men as partners.

While the methods& products we have today surpass those used by our ancestors by a long shot, you may be surprised to hear that contraception goes way, way back!

Researchers believe a French cave painting, which could be 15,000 years old, depicts what some think is the first illustration of a man wearing a condom. Similarly, there are mentions of condoms in Greek legends that date back to 3000 BC specifically that of the infamous King Minos of Crete.

The 18th-century memoirs of Giacomo Casanova also show us that Casanova believed he "invented" a type of cervical cap, which was made of partly squeezed lemon halves. However, researchers believe these "caps" were probablyused asprotection against venereal disease rather than pregnancy.

RELATED: Taking Control Of My Body: Why I Quit Birth Control After 12 Years

Yona Dervishi is a writer who is currently working at YourTango as an editorial intern. She covers topics pertaining to health & wellness, news, and entertainment.

See the original post:
10 Surprising Facts About Birth Control (That You Probably Never Knew) - YourTango

Posted in Human Genetics | Comments Off on 10 Surprising Facts About Birth Control (That You Probably Never Knew) – YourTango

Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual…

Posted: October 16, 2021 at 2:30 am

NEW YORK, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS EURONEXT GROWTH: ALCLS) (the Company), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for genetic diseases, announced today that pre-clinical data that support anti-tumor activity of UCARTMESO will be presented at the Society for Immunotherapy of Cancers 36th Annual Meeting (SITC 2021), to be held in Washington, D.C. and virtually on November 10 to 14, 2021.

Cellectis will present a poster on UCARTMESO, an allogeneic CAR-T cell product candidate targeting mesothelin - expressing solid tumors. Mesothelin is a tumor-associated antigen that is highly and consistently expressed in mesothelioma and pancreatic cancer and is also over-expressed in subsets of other solid tumors (ovarian cancer, non-small cell lung cancer, gastric cancer, triple-negative breast cancer). UCARTMESO also leverages its TALEN gene editing technology to resist immune suppression mediated by TGF.

Last May, during its Innovation Days, Cellectis announced the development of the new pre-clinical UCART product candidates targeting B-cell lymphomas and venturing for the first time into the solid tumor space.

Presentation Details:

Title: Mesothelin (MSLN) targeting allogeneic CAR-T cells engineered to overcome tumor immunosuppressive microenvironmentPoster Number: 143Presenter: Roman Galetto, Ph.D, Director, Preclinical and Program ManagementDate/Time: Friday November 12, 7:00AM - 8:30PM, Walter E. Washington Convention Center, Poster Hall (Hall E)

Full text of the abstracts will be released on the SITC website at 7:00 a.m. ET on November 12, 2021.

About Cellectis Cellectis is a gene editing company, developing first of its kind therapeutic products. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to achieve therapeutic gene editing in hemopoietic stem cells for various genetic disorders. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing cell therapy product candidates utilizing TALEN, its gene editing technology, and PulseAgile, its pioneering electroporation system in order to treat diseases with unmet medical needs. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomal storage diseases. Cellectis headquarters are in Paris, France, with locations in New York City, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

Story continues

For more information, visit http://www.cellectis.com Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

For further information, please contact:

Media contacts: Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300 Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com

Investor Relation contact: Eric Dutang, Chief Financial Officer, +1 (646) 630 1748, investor@cellectis.com

Forward-looking Statements

This presentation contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as at this time, anticipate, believe, expect, on track, plan, scheduled, and will, or the negative of these and similar expressions. These forward-looking statements, which are based on our managements current expectations and assumptions and on information currently available to management, include statements about our research and development projects and priorities, our pre-clinical project development efforts and the timing of our presentation of data. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development as well as the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation. With respect to our cash runway, our operating plans, including product development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2020 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Attachment

Original post:
Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual...

Posted in New York Stem Cells | Comments Off on Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual…

Judge Rules to Uphold Religious Exemption to NY Vax Mandate – wnbf.com

Posted: October 16, 2021 at 2:30 am

New York must allow unvaccinated health care workers who object to getting the COVID-19 vaccine due to religious beliefs to remain on the job, at least for now.

New York Governor Kathy Hochul, however, vows the fight over mandatory COVID-19 vaccinations for health care workers isnt over following a federal judge ruling upholding religious exemptions.

A federal judge has ruled that New York must continue to allow health care workers to seek exemptions from a statewide COVID-19 vaccine mandate on religious grounds as a lawsuit challenging the requirement proceeds.

Judge David Hurd in Utica had issued a temporary restraining order a month ago after 17 doctors, nurses and other health professionals claimed in a lawsuit that their rights would be violated with a vaccine mandate that disallowed the exemptions. The group filed a suit against the state mandate on the grounds that getting the vaccine, in their claim, would cause them to sin as they maintained fetal stem cells were used in the research and development of the shots.

Hurds ruling October 12 means New York will continue to be barred from enforcing any requirement that employers deny religious exemptions.Judge Hurd says, however, the issues surrounding the case merits the expected appeals.

Governor Hochul issued a brief statement following the ruling saying, My responsibility as Governor is to protect the people of this state, and requiring health care workers to get vaccinated accomplishes that. I stand behind this mandate and I will fight this decision in court to keep New Yorkers safe.

KEEP READING: Learning From Mistakes During the Spanish Flu

Read the original:
Judge Rules to Uphold Religious Exemption to NY Vax Mandate - wnbf.com

Posted in New York Stem Cells | Comments Off on Judge Rules to Uphold Religious Exemption to NY Vax Mandate – wnbf.com

Page 630«..1020..629630631632..640650..»